share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4:持股变动声明-董事 Borgeson Blake
美股sec公告 ·  07/25 18:19
Moomoo AI 已提取核心信息
Blake Borgeson, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on July 23, 2024. The transaction was executed on the open market at a price of $8.4774 per share, resulting in a total sale value of approximately $97,040.80. Following the sale, Borgeson's direct holdings in the company amount to 7,155,663 shares. The sale reflects a transaction in the company's common stock and is part of the normal course of trading activities.
Blake Borgeson, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on July 23, 2024. The transaction was executed on the open market at a price of $8.4774 per share, resulting in a total sale value of approximately $97,040.80. Following the sale, Borgeson's direct holdings in the company amount to 7,155,663 shares. The sale reflects a transaction in the company's common stock and is part of the normal course of trading activities.
Blake Borgeson,与Recursion Pharmaceuticals,Inc. [RXRX]有关,于2024年7月23日出售了11,447股A类普通股。该交易在开放市场上以每股8.4774美元的价格执行,总销售价值约为97,040.80美元。售出后,Borgeson在公司中的直接持股总额为7,155,663股。此次出售反映了该公司普通股的交易,是正常交易活动的一部分。
Blake Borgeson,与Recursion Pharmaceuticals,Inc. [RXRX]有关,于2024年7月23日出售了11,447股A类普通股。该交易在开放市场上以每股8.4774美元的价格执行,总销售价值约为97,040.80美元。售出后,Borgeson在公司中的直接持股总额为7,155,663股。此次出售反映了该公司普通股的交易,是正常交易活动的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息